Prmt5 inhibitors and uses thereof
US-2016137631-A1 · May 19, 2016 · US
Arginine methyltransferase inhibitors and uses thereof
US9598374B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9598374-B2 |
| Application number | US-201414775794-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 14, 2014 |
| Priority date | Mar 14, 2013 |
| Publication date | Mar 21, 2017 |
| Grant date | Mar 21, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound of formula: or a pharmaceutically acceptable salt thereof. 2. The compound of claim 1 , wherein the compound is: 3. The compound of claim 1 , wherein the compound is a pharmaceutically acceptable salt of: 4. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. 5. A pharmaceutical composition comprising a compound of claim 2 , and a pharmaceutically acceptable excipient. 6. A pharmaceutical composition comprising a compound of claim 3 , and a pharmaceutically acceptable excipient. 7. A kit or packaged pharmaceutical comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and instructions for use thereof. 8. A kit or packaged pharmaceutical comprising a compound of claim 2 , and instructions for use thereof. 9. A kit or packaged pharmaceutical comprising a compound of claim 3 , and instructions for use thereof.
Assignees
Inventors
Classifications
Drugs for disorders of the cardiovascular system · CPC title
Immunomodulators · CPC title
Antineoplastic agents · CPC title
Drugs for immunological or allergic disorders · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9598374B2 cover?
- Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described.
- Who is the assignee on this patent?
- Epizyme Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D231/12. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 21 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).